reglab/housing_qa huggingface dataset:
DC Code § 48-851.02 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8F - Safe Disposal of Unused Pharmaceuticals|§ 48-851.02. Safe disposal of unused pharmaceuticals

(a)(1) The Board of Pharmacy shall design a public education campaign to educate individuals on: (A) The importance of promptly disposing of unused pharmaceuticals to avoid accidental overdoses, medication errors, and household drug theft; (B) How disposing of pharmaceuticals by flushing them into the public sewer system or throwing them in the trash can be harmful to the environment and can contaminate the drinking water supply; and (C) How to dispose of unused pharmaceuticals in a safe and environmentally sound manner. (2) Each retail pharmacy licensed in the District of Columbia shall implement the public education campaign as required by the Board of Pharmacy. (b)(1) By July 1, 2010, the Board of Pharmacy shall make recommendations to the Mayor regarding the establishment of a program to enable consumers to dispose of unused pharmaceuticals, including controlled substances, in a safe and environmentally sound manner. (2) In developing recommendations, the Board of Pharmacy shall give consideration to a mail-in program that: (A) Utilizes prepaid mailing envelopes that allow an individual to mail unused pharmaceuticals to a single collection location approved for all pharmaceuticals including controlled substances; (B) Distributes the prepaid mailing envelopes to the public at various locations, including to all retail pharmacies; (C) Provides for the collected pharmaceuticals to be disposed of in a manner that is: (i) Safe; (ii) Secure; (iii) Environmentally sound; and (iv) In compliance with District and federal environmental requirements; and (D) Randomly assesses the toxicity of pharmaceuticals received; provided, that the assessment results do not identify the: (i) Patient; (ii) Person who mailed the material; (iii) Prescriber; or (iv) Pharmacy.  (Mar. 5, 2010, D.C. Law 18-112, § 3, 56 DCR 9378.)  Section References This section is referenced in § 48-851.04.
DC Code § 48-851.03 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8F - Safe Disposal of Unused Pharmaceuticals|§ 48-851.03. Disposal of pharmaceuticals by health care facilities

(a) Effective January 1, 2011, it shall be unlawful for a health care facility to dispose of any pharmaceutical product, used or unused, by flushing the product down a drain or by any other method that utilizes the public sewer system, except as authorized by the Mayor through rulemaking. (b) A health care facility that is determined to have disposed of a pharmaceutical product in a manner prohibited by this chapter or by rules issued pursuant to this chapter shall be subject to a civil fine of up to $1,000 per occurrence and required to submit to the Board of Pharmacy a mitigation plan designed to prevent further occurrences.  (Mar. 5, 2010, D.C. Law 18-112, § 4, 56 DCR 9378.)  Section References This section is referenced in § 48-851.04.
DC Code § 48-851.04 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8F - Safe Disposal of Unused Pharmaceuticals|§ 48-851.04. Rules

(a) The Mayor, pursuant to subchapter I of Chapter 5 of Title 2 [§ 2-501 et seq.], shall issue rules to implement the provisions of § 48-851.03. The rules shall specify safe, secure, and environmentally sound methods for health care facilities to dispose of used and unused pharmaceuticals. (b) The Mayor, pursuant to subchapter I of Chapter 5 of Title 2 [§ 2-501 et seq.], may issue rules to implement the provisions of § 48-851.02.  (Mar. 5, 2010, D.C. Law 18-112, § 5, 56 DCR 9378.)  Editor's Notes Revision of chapter: D.C. Law 4-29 enacted the District of Columbia Uniform Controlled Substances Act of 1981. D.C. Law 4-29 repealed former §§ 33-501, 33-503 to 33-513, 33-515 to 33-520, 33-521(a), (c) through (g), and 33-522 to 33-526 1981 Ed., redesignated former §§ 33-502, 33-514, and 33-521 1981 Ed. as present §§ 48-921.01, 48-921.02, and 48-931.01, respectively, and enacted present §§ 48-901.02, 48-902.01 to 48-902.13, 48-903.01 to 48-903.09, 48-904.01 to 48-904.10, 48-905.01 to 48-905.07, and 48-906.01 to 48-906.03. Former § 33-509 1981 Ed. had been amended by D.C. Law 4-25. Former §§ 33-501 to 33-526 1981 Ed. as they existed prior to the revision of this chapter by D.C. Law 4-29, were part of the Uniform Narcotic Drug Act, approved June 20, 1938 (52 Stat. 785). D.C. Law 4-29 also repealed, inter alia, the provisions of former chapter 6 of this title, the Dangerous Drug Act for the District of Columbia, approved July 24, 1956 (70 Stat. 612).
DC Code § 48-853.02 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8G - Prescription Drug Monitoring|§ 48-853.02. Program establishment; Director’s authority

(a) There is established the Prescription Drug Monitoring Program within the Department. The Program shall: (1) Establish, maintain, and administer an electronic system to monitor the dispensing of covered substances; (2) Provide dispensers with a basic file layout to enable electronic transmission of the information required under this chapter; and (3) Establish and maintain a process for verifying the credentials of and authorizing the use of prescription information by those individuals and agencies listed in § 48-853.05(b) and (c). (b) The Director may contract with another District agency or a private vendor as may be necessary for the implementation and maintenance of the Program. Any such contractor shall be bound to comply with the provisions regarding confidentiality of data in this chapter and shall be subject to the penalties specified in this chapter. (c) The Director shall also establish a multi-discipline advisory committee, which shall function under the Department to assist in the implementation and evaluation of the Program.  (Feb. 22, 2014, D.C. Law 20-66, § 3, 61 DCR 7.)  Section References This section is referenced in § 48-853.01.
DC Code § 48-853.03a (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8G - Prescription Drug Monitoring|§ 48-853.03a. Registration requirement for prescribers and dispensers. [Repealed]

Repealed.  (Feb. 22, 2014, D.C. Law 20-66, § 4a; as added Apr. 11, 2019, D.C. Law 22-288, § 401(a), 66 DCR 1656; June 24, 2020, D.C. Law 23-116, § 4(a), 67 DCR 5081.)  Emergency Legislation  For temporary (90 days) repeal of applicability provision of D.C. Law 22-288, see § 7168 of Fiscal Year 2020 Budget Support Congressional Review Emergency Act of 2019 (D.C. Act 23-112, Sept. 4, 2019, 66 DCR 11964).   For temporary (90 days) repeal of applicability provision of D.C. Law 22-288, see § 7168 of Fiscal Year 2020 Budget Support Emergency Act of 2019 (D.C. Act 23-91, July 22, 2019, 66 DCR 8497).
DC Code § 48-853.03b (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8G - Prescription Drug Monitoring|§ 48-853.03b. Registration requirement for practitioners and dispensers

(a) Any practitioner who is licensed, registered, or otherwise permitted to prescribe, distribute, dispense, conduct research with respect to, or to administer a controlled substance or other covered substance in the course of his or her professional practice, and any dispenser who is licensed in the District of Columbia to dispense a controlled substance or other covered substance to an ultimate user, the user's agent, or owner in the case of animals, shall be registered with the Program. (b) Beginning 90 days afterJune 24, 2020, each practitioner or dispenser who is required to be registered with the Program, pursuant to subsection (a) of this section, shall register with the Program within 90 days of obtaining a new health professional license or before renewing an existing health professional license, whichever occurs first. (c) The Health Occupations Boards shall not approve a practitioner or dispenser, who is required to be registered with the Program pursuant to subsection (a) of this section, for reinstatement, reactivation, or renewal of licensure without proof that the practitioner or dispenser has registered with the Program as required. (d) Failure to timely register with the Program shall constitute grounds for disciplinary action by the relevant health occupations board pursuant to § 3-1205.14(c), and the imposition of civil fines pursuant to § 2-1801.04.  (Feb. 22, 2014, D.C. Law 20-66, § 4b; as added June 24, 2020, D.C. Law 23-116, § 4(b), 67 DCR 5081.)
DC Code § 48-853.04 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8G - Prescription Drug Monitoring|§ 48-853.04. Authority to access database

(a) A prescriber or dispenser authorized to access the information in the possession of the Program pursuant to this chapter may delegate, pursuant to regulations promulgated by the Director to implement the provisions of this section, such authority to up to 2 health care professionals who are: (1) Licensed, registered, or certified by a health occupations board; and (2) Employed at the same facility and under the direct supervision of the prescriber or dispenser. (b) No prescriber or dispenser shall provide false or misleading information to the Department with the intent to obtain unauthorized access to, or alter the information in the possession of the Program. (c) A violation of subsection (b) of this section shall constitute grounds for: (1) The revocation, suspension, or denial of a District controlled substances registration; (2) Disciplinary action by the relevant health occupations board pursuant to § 3-1205.14(c); and (3) The imposition of civil fines pursuant to § 2-1801.04.  (Feb. 22, 2014, D.C. Law 20-66, § 5, 61 DCR 7; Apr. 11, 2019, D.C. Law 22-288, § 401(b), 66 DCR 1656.)  Emergency Legislation  For temporary (90 days) repeal of applicability provision of D.C. Law 22-288, see § 7168 of Fiscal Year 2020 Budget Support Congressional Review Emergency Act of 2019 (D.C. Act 23-112, Sept. 4, 2019, 66 DCR 11964).   For temporary (90 days) repeal of applicability provision of D.C. Law 22-288, see § 7168 of Fiscal Year 2020 Budget Support Emergency Act of 2019 (D.C. Act 23-91, July 22, 2019, 66 DCR 8497).
DC Code § 48-853.06 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8G - Prescription Drug Monitoring|§ 48-853.06. Interoperability; information exchange with other prescription drug monitoring programs

(a) The Director may enter into written agreements with other prescription drug monitoring programs, or a third party, approved by the Director, that operates an interstate prescription drug monitoring exchange, for the purpose of interoperability and the mutual exchange of information among prescription drug monitoring programs, and describing the terms and conditions for the sharing of prescription information under this section. (b) The Director may provide prescription monitoring information pursuant to such agreements, which shall only use the information for the purposes allowed by this chapter. (c) The Director may request and receive prescription drug monitoring information from other states’ prescription drug monitoring programs and may use the information under the provisions of this chapter.  (Feb. 22, 2014, D.C. Law 20-66, § 7, 61 DCR 7.)
DC Code § 48-853.07 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8G - Prescription Drug Monitoring|§ 48-853.07. Criteria for indicators of misuse; Director’s authority to disclose information; intervention

(a) The Director may establish through rulemaking: (1) Criteria for indicators of misuse or abuse of covered substances; (2) A method for analysis of data collected by the Program using the criteria for indicators of misuse or abuse of covered substances; (3) Criteria for indications of a possible violation of law or a possible breach of professional standards by a prescriber or dispenser; and (4) A method for analysis of data collected by the Program using the criteria for indications of a possible violation of law or a possible breach of professional standards by a prescriber or dispenser. (b)(1) Upon the development of the criteria and data analysis, the Program may review prescription monitoring program data for indications of: (A) Possible misuse or abuse of a covered prescription drug; and (B) A possible violation of law or possible breach of professional standards by a prescriber or a dispenser. (2) If the Program's review of prescription monitoring data indicates a possible violation of paragraph (1) of this subsection, the Director may, in addition to any discretionary disclosure of information pursuant to this chapter: (A) Report the possible misuse or abuse by a patient to the specific prescriber or dispenser of the covered prescription drug for the purpose of intervention to prevent such misuse or abuse; (B) Notify the prescriber or dispenser of the possible violation of law or possible breach of professional standards; and (C) Provide education to the prescriber or dispenser.  (Feb. 22, 2014, D.C. Law 20-66, § 8, 61 DCR 7; Apr. 11, 2019, D.C. Law 22-288, § 401(d), 66 DCR 1656.)  Emergency Legislation  For temporary (90 days) repeal of applicability provision of D.C. Law 22-288, see § 7168 of Fiscal Year 2020 Budget Support Congressional Review Emergency Act of 2019 (D.C. Act 23-112, Sept. 4, 2019, 66 DCR 11964).   For temporary (90 days) repeal of applicability provision of D.C. Law 22-288, see § 7168 of Fiscal Year 2020 Budget Support Emergency Act of 2019 (D.C. Act 23-91, July 22, 2019, 66 DCR 8497).
DC Code § 48-853.08 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8G - Prescription Drug Monitoring|§ 48-853.08. Immunity from liability

(a) The Director and the employees of the Department shall not be liable for any civil damages resulting from the accuracy or inaccuracy of any information reported, compiled, or maintained by the Program pursuant to this chapter. (b) The Director and the employees of the Department shall not be liable for any civil damages resulting from the disclosure of or failure to disclose any information in compliance with this chapter and the Department’s regulations. (c) In the absence of gross negligence or willful misconduct, prescribers or dispensers complying in good faith with the reporting requirements of this chapter shall not be liable for any civil damages for any act or omission resulting from the submission of such required reports.  (Feb. 22, 2014, D.C. Law 20-66, § 9, 61 DCR 7.)
DC Code § 48-853.09 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8G - Prescription Drug Monitoring|§ 48-853.09. Unlawful disclosure of information and acts; disciplinary action authorized; penalties

(a) It shall be unlawful for any person having access to the confidential information in possession of the Program or any data or reports produced by the Program to disclose the confidential information except as provided in this chapter. Any person who discloses this confidential information in violation of the provisions of this chapter shall be guilty of a misdemeanor upon conviction. (b) It shall be unlawful for any person who lawfully receives confidential information from the Program to redisclose or use the confidential information in any way other than the authorized purpose for which the request was made. Any person who discloses confidential information in violation of this chapter shall be guilty of a misdemeanor upon conviction. (c) Nothing in this section shall prohibit a person who prescribes or dispenses a covered substance required to be reported to the program from redisclosing information obtained from the Program to another prescriber or dispenser who has prescribed or dispensed a covered substance to the same patient. (d) Unauthorized use or disclosure of confidential information received from the Program shall also be grounds for disciplinary action by the relevant health occupations board.  (Feb. 22, 2014, D.C. Law 20-66, § 10, 61 DCR 7.)
DC Code § 48-853.10 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8G - Prescription Drug Monitoring|§ 48-853.10. Rules

The Director, pursuant subchapter I of Chapter 5 of Title 2 [§ 2-501 et seq.], shall issue rules to implement the provisions of this chapter, including the establishment of criteria for granting waivers to the reporting requirements set forth in this chapter.  (Feb. 22, 2014, D.C. Law 20-66, § 11, 61 DCR 7.)
DC Code § 48-855.02 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8H - Specialty Drug Copayment Limitation|§ 48-855.02. Specialty drug copayment or coinsurance limitation

(a)(1) A health benefit plan that provides coverage for prescription drugs shall ensure that a required copayment or coinsurance applicable to a drug on a specialty tier does not exceed $150 per month for up to a 30-day supply of the specialty drug or $300 for a 90-day supply. (2) On July 1 of each year, the limit on a required copayment or coinsurance applicable to a drug on a specialty tier provided in paragraph (1) of this subsection shall increase by a percentage equal to the percentage change from the preceding year in the medical care component of the March Consumer Price Index for All Urban Consumers, Washington-Arlington-Alexandria, DC-VA-MD-WV metropolitan area, as published by the Bureau of Labor Statistics of the United States Department of Labor. (b)(1) For a health benefit plan that provides coverage for prescription drugs and utilizes a tiered formulary, a member or member representative shall have the right to request that a non-preferred drug be covered under the cost sharing applicable for preferred drugs if the prescribing physician determines that the preferred drug for treatment of the same condition either would not be as effective for the individual or would have adverse effects for the individual, or both. (2) The denial of a request made pursuant to paragraph (1) of this subsection shall be considered an adverse event and shall be subject to the health benefit plan's internal review process. (c) A health benefit plan that provides coverage for prescription drugs shall not place all drugs in a given class of drugs on a specialty tier. (d) Nothing in this section shall be construed to require a health benefit plan to: (1) Provide coverage for any additional drugs not otherwise required by law; (2) Implement specific utilization management techniques, such as prior authorization or step therapy; or (3) Cease the use of tiered cost-sharing structures, including strategies used to incentivize use of preventive services, disease management, and low-cost treatment options. (e) Nothing in this section shall be construed to require a pharmacist to substitute a drug without the consent of the prescribing physician. (f) A health insurer shall not be precluded from requiring specialty drugs to be obtained through a designated pharmacy or other source of specialty drugs.  (Apr. 7, 2017, D.C. Law 21-248, § 3, 64 DCR 1624; Mar. 16, 2021, D.C. Law 23-252, § 2(b), 68 DCR 001151.)
DC Code § 48-855.02a (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8H - Specialty Drug Copayment Limitation|§ 48-855.02a. Insulin copayment or coinsurance limitation

(a) A health insurer that provides coverage for prescription insulin drugs pursuant to the terms of a health benefits plan the insurer offers shall limit the total amount that an insured is required to pay for a 30-day supply of covered prescription insulin drugs at an amount not to exceed $30, regardless of the quantity or type of covered prescription insulin drug used to fill the insured's prescription. (b) A health insurer that provides coverage for diabetes devices and diabetic ketoacidosis devices pursuant to the terms of a health benefits plan offered by the insurer, shall limit the total amount that an insured is required to pay for a 30-day supply of all medically necessary covered diabetes devices and diabetic ketoacidosis devices that are in accordance with the insured's diabetes treatment plan at an amount not to exceed $100. (c) Pursuant to subsections (a) and (b) of this section, prescription insulin drugs, diabetes devices, and diabetic ketoacidosis devices shall be covered without being subject to a deductible and any cost sharing paid by an insured shall be applied toward the insured's deductible obligation. (d) Nothing in this section prevents an insurer from reducing an insured's copayment or coinsurance by an amount greater than the amount specified in subsections (a) and (b) of this section. (e) On July 1 of each year, the limit on a required copayment or coinsurance an insured is required to pay under subsections (a) and (b) of this section shall increase by a percentage equal to the percentage change from the preceding year in the medical care component of the Consumer Price Index for All Urban Consumers, Washington-Arlington-Alexandria, DC-VA-MD-WV metropolitan area, as published by the Bureau of Labor Statistics of the United States Department of Labor. (f) This section shall apply as of January 1, 2022.  (April 7, 2017, D.C. Law 21-248, § 3a; as added Mar. 16, 2021, D.C. Law 23-252, § 2(d), 68 DCR 001151.)
DC Code § 48-855.03 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 8H - Specialty Drug Copayment Limitation|§ 48-855.03. Applicability

This chapter shall apply to a health benefit plan effective, or renewed, on or after January 1, 2018; except, that § 48-855.02a shall apply on January 1, 2022[].  (Apr. 7, 2017, D.C. Law 21-248, § 4, 64 DCR 1624; Mar. 16, 2021, D.C. Law 23-252, § 2(c), 68 DCR 001151.)
DC Code § 48-921.51 (2021)
2021 District of Columbia Code|Title 48 - Foods and Drugs|Chapter 9C - Entheogenic Plant and Fungus Policy|§ 48-921.51. Findings and declaration of policy

(a) The people of the District of Columbia find that use of entheogenic plants and fungi have been demonstrated, through scientific studies, to be beneficial in addressing a variety of afflictions, including substance abuse, addiction, trauma, post-traumatic stress syndrome, chronic depression, anxiety, diabetes, cluster headaches, and other conditions; and that practices with entheogenic plants and fungi have long existed, have been considered sacred to a number of cultures and religions for millennia, and continue to be enhanced and improved. Citizens of the District of Columbia seeking to improve their health and well-being through the use of entheogenic plants and fungi currently use them in fear of arrest and prosecution. (b) It is declared that the policy of this chapter is to make investigation and arrest of adults for non-commercial planting, cultivating, purchasing, transporting, distributing, possessing, or engaging in practices with entheogenic plants and fungi among the lowest law enforcement priorities for the District of Columbia.  (Mar. 16, 2021, D.C. Law 23-268, § 2, 68 DCR 001376.)  Editor's Notes  This section was created by Initiative No. 81, the Entheogenic Plant and Fungus Policy Act of 2020, D.C. Law 23-268, March 16, 2021, 68 DCR 1376.